Utility of autologous fecal microbiota transplantation and elucidation of microbiota in diversion colitis.
Enterobacteriaceae
colostomy
diversion colitis
fecal microbiota transplantation
intestinal microbiota
Journal
DEN open
ISSN: 2692-4609
Titre abrégé: DEN Open
Pays: Australia
ID NLM: 9918317682706676
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
received:
13
07
2021
revised:
08
09
2021
accepted:
12
09
2021
entrez:
21
3
2022
pubmed:
22
3
2022
medline:
22
3
2022
Statut:
epublish
Résumé
Diversion colitis (DC) is an inflammatory disorder caused by interruption of the fecal stream and subsequent nutrient deficiency from luminal bacteria. The utility of fecal microbiota transplantation (FMT) for DC was recently investigated; however, the precise pathogenesis of this condition remains unclear. This study aimed to evaluate the utility of autologous FMT in DC and to determine the related changes in the intestinal microbiota. Autologous FMT was performed to reestablish the intestinal microbiota in five patients (average age, 64.6 ± 8.3 years) with DC. They underwent double-ended colostomy. We assessed the diverted colon by endoscopy and evaluated the microbiota before and after FMT using the 16S rRNA gene sequencing method. All five patients had mild inflammation (ulcerative colitis endoscopic index of severity [UCEIS] 2-3) in the diverted colon based on the colonoscopic findings. Three patients presented with symptoms, such as tenesmus, mucoid stool, and bloody stool. With FMT treatment, all patients achieved endoscopic remission (UCEIS score of 0 or 1) and symptomatic improvement. We observed a significantly decreased α-diversity in DC patients compared to healthy controls. The frequency of aerobic bacteria, such as This study was the first to show that the microbiota in the diverted colon was significantly affected by autologous FMT. Since interruption of the fecal stream is central to the development of DC, FMT can be considered a promising treatment.
Identifiants
pubmed: 35310733
doi: 10.1002/deo2.63
pii: DEO263
pmc: PMC8828251
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e63Informations de copyright
© 2021 The Authors. DEN Open published by John Wiley & Sons Australia, Ltd on behalf of Japan Gastroenterological Endoscopy Society.
Déclaration de conflit d'intérêts
Miyarisan Pharmaceutical Co. Ltd. supported this study in the analysis of the microbiota.
Références
Gut. 1991 Sep;32(9):1020-3
pubmed: 1916483
Gut. 1993 Mar;34(3):382-5
pubmed: 8472988
Gastroenterology. 1984 Sep;87(3):710-3
pubmed: 6745620
Curr Protoc Bioinformatics. 2011 Dec;Chapter 10:Unit 10.7.
pubmed: 22161565
Inflamm Bowel Dis. 2019 Mar 14;25(4):e29-e30
pubmed: 30534963
Biochem Biophys Rep. 2020 Dec 30;25:100892
pubmed: 33458259
Gut. 2016 Sep;65(9):1574-5
pubmed: 27340192
Gut. 1989 Aug;30(8):1094-8
pubmed: 2767506
Tech Coloproctol. 2015 Jan;19(1):51-2
pubmed: 25300242
Hum Pathol. 1990 Apr;21(4):429-36
pubmed: 2318485
World J Gastroenterol. 2018 Apr 28;24(16):1734-1747
pubmed: 29713128
Mol Biol Evol. 2012 Dec;29(12):3947-58
pubmed: 22915830
Nucleic Acids Res. 2013 Jan 7;41(1):e1
pubmed: 22933715
Gastroenterology. 1981 Mar;80(3):438-41
pubmed: 7450438
Biol Pharm Bull. 2014;37(12):1899-906
pubmed: 25451839
J Gastroenterol. 2012 Dec;47(12):1298-307
pubmed: 22576027
Inflamm Bowel Dis. 2007 Aug;13(8):955-62
pubmed: 17455205
Gut. 2019 Apr;68(4):593-758
pubmed: 29588334
Genome Biol. 2011 Jun 24;12(6):R60
pubmed: 21702898
Acta Chir Iugosl. 2008;55(3):77-81
pubmed: 19069697
Gut Liver. 2014 Mar;8(2):170-6
pubmed: 24672659